Study finds Covaxin produced neutralising titres against India, UK variants

Modest reduction in neutralisation by a factor of 1.95 against B.1.617 variant compared to vaccine variant D614G

Citing a study published in peer-reviewed medical journal Clinical Infectious Diseases, Bharat Biotech has claimed that its COVID-19 vaccine ”Covaxin” has been found to be effective against coronavirus strains found in India and the UK.

In a media release, the Hyderabad-based vaccine major noted that vaccination with Covaxin produced neutralising titres against all key emerging variants tested, including B.1.617 and B.1.1.7, first identified in India and the UK, respectively.

The study was conducted in collaboration with the National Institute of Virology and Indian Council of Medical Research, it added.

“Covaxin gets international recognition yet again, by scientific research data published demonstrating protection against the new variants. Yet another feather in its cap,” Bharat Biotech co-founder and Joint Managing Director Suchitra Ella said in a tweet. She also tagged PMO India, Finance Minister Nirmala Sitharaman and Health Minister Harsh Vardhan, among others, in the tweet.

The study found a modest reduction in neutralisation by a factor of 1.95 against B.1.617 variant compared to vaccine variant D614G, Bharat Biotech noted.

Despite this reduction, neutralising titre levels with B.1.617 remain above levels expected to be protective, it added.